Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | CTSS | P25774 | 3/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | KLK7 | P49862 | 2/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 2/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14264179 | 0.90 | SYK (0.56) | PPARASYKCTSSATMCTSL | |
| SCHEMBL20854198 | 0.86 | SYK (0.54) | PPARASYKPPARGCTSSATM | |
| SCHEMBL7658308 | 0.86 | SYK (0.54) | PPARASYKPPARGCTSSATM | |
| SCHEMBL15157049 | 0.86 | PPARA (0.54) | PPARASYKPPARGCTSSATM | |
| SCHEMBL15156830 | 0.86 | PPARA (0.54) | PPARASYKPPARGCTSSATM | |
| SCHEMBL20885274 | 0.86 | SYK (0.54) | PPARASYKPPARGCTSSATM | |
| SCHEMBL20885281 | 0.86 | SYK (0.54) | PPARASYKPPARGCTSSATM | |
| SCHEMBL22579840 | 0.86 | SYK (0.54) | PPARASYKPPARGCTSSATM | |
| SCHEMBL28290407 | 0.84 | SYK (0.57) | PPARASYKPPARGCTSSATM | |
| SCHEMBL6386141 | 0.84 | PPARA (0.47) | PPARASYKPPARGCTSSATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11479579-B2 | Therapeutic compounds and methods | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2022-10-25 | — | — | US | disclosed |
| US-20210277055-A1 | THERAPEUTIC COMPOUNDS AND METHODS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2021-09-09 | — | — | US | disclosed |
| US-6344452-B1 | GASTRIN RECEPTOR ANTAGONIST, GASTROINTESTINAL DISORDERS, ETC | ZERIA PHARMACEUTICALS CO., LTD. (JP) | 2002-02-05 | — | — | US | disclosed |
| EP-1085014-A1 | 1,5-BENZODIAZEPINE DERIVATIVES | Zeria Pharmaceutical Co., Ltd. (JP) | 2001-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479579-B2 | Therapeutic compounds and methods | SNCA, PARK7, PSEN2 | PPARA 2032/4885SYK 3900/4885PPARG 1379/4885 |
| US-20210277055-A1 | THERAPEUTIC COMPOUNDS AND METHODS | SNCA, PARK7, PSEN2 | PPARA 2032/4885SYK 3900/4885PPARG 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.